Video

What the impact of 44-week aflibercept data may mean in a real-world setting

Author(s):

Sheryl Stevenson,Emily Kaiser Maharjan
Conferences|ASRS Preview

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) AGS 2025: Long-term efficacy and safety of standalone and phaco ELT with Marc Toeteberg-Harms, MD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Related Content
Study demonstrates visual acuity improvements following gene therapy for AIPL1-associated inherited retinal dystrophies
February 28th 2025

Study demonstrates visual acuity improvements following gene therapy for AIPL1-associated inherited retinal dystrophies

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: StockAdobe/Andrija)
February 25th 2025

Australian Society of Ophthalmologists announces new board appointments

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Low-dose atropine causes esotropia in patient case
February 24th 2025

Low-dose atropine causes esotropia in patient case

EMA validates indication extension application of pegcetacoplan for treatment of kidney disease
February 23rd 2025

EMA validates indication extension application of pegcetacoplan for treatment of kidney disease

© 2025 MJH Life Sciences

All rights reserved.